Elamipretide

Elamipretide
Clinical data
Trade names	Forzinity
Other names	SS-31, MTP-131, Bendavia
License data	US DailyMed: Elamipretide;
Routes of; administration	Subcutaneous
ATC code	None;
Legal status
Legal status	US: ℞-only;
Identifiers
	IUPAC name (2S)-6-Amino-2-[[(2S)-2-[[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]amino]-N-[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]hexanamide;
CAS Number	736992-21-5; as HCl: 72244098-12-0;
PubChem CID	11764719;
DrugBank	DB11981;
ChemSpider	9939410;
UNII	87GWG91S09; as HCl: E40WZ3BK2D;
KEGG	D10925; as HCl: D11542;
CompTox Dashboard (EPA)	DTXSID50471988 ;
Chemical and physical data
Formula	C32H49N9O5
Molar mass	639.802 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=CC(O)=CC(C)=C1C[C@H](NC(=O)[C@H](N)CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CC=CC=C2)C(N)=O;
	InChI InChI=1S/C32H49N9O5/c1-19-15-22(42)16-20(2)23(19)18-27(41-29(44)24(34)11-8-14-38-32(36)37)31(46)39-25(12-6-7-13-33)30(45)40-26(28(35)43)17-21-9-4-3-5-10-21/h3-5,9-10,15-16,24-27,42H,6-8,11-14,17-18,33-34H2,1-2H3,(H2,35,43)(H,39,46)(H,40,45)(H,41,44)(H4,36,37,38)/t24-,25+,26+,27+/m1/s1; Key:SFVLTCAESLKEHH-WKAQUBQDSA-N;

Elamipretide (development codes SS-31, MTP-131), sold under the brand name Forzinity, is a medication used for the treatment of Barth syndrome. Elamipretide is a mitochondrial cardiolipin binder. It is used as the hydrochloride salt. It is given by injection under the skin (subcutaneous).

The most common side effects identified in clinical trials include mild-to-moderate injection site reactions.

Elamipretide was approved for medical use in the United States in September 2025.